C¹⁷ Research Network

The C¹⁷ Research Network operates under the auspices of the C¹⁷ Council, a non-profit organization that represents the 16 academic pediatric oncology/hematology programs in the 17 centres across Canada. The C¹⁷ Research Network drives collaborative, multi‑disciplinary, multi‑site Canadian research in pediatric hematology, oncology, and stem‑cell transplantation, operating a peer‑reviewed grant competition that supports trials, registries, biobanks, Quality of Life (QoL), outcomes, health services, and translational studies.

C¹⁷ Research Network Operating Grant Competition

The C¹⁷ Research Network holds an annual peer-reviewed grant competition to fund projects in pediatric hematology, oncology and hematological stem cell transplantation. The grant review process ranks applications based on criteria including clear statement of research, methodology, innovativeness and originality, evidence of collaboration and multidisciplinary approach and impact or application into clinical practice. The scope of projects considered include but are not limited to: phase I, II, III and pilot clinical trials; registries and population based studies; biological sample banks; quality of life and psychosocial research; health outcomes and health service research; and basic laboratory and translational research. Note that applications are welcome for projects with a justification to function as a single centre, although collaboration is strongly encouraged. New collaborations, mentorship and applications from Young Investigators also are encouraged.

By encouraging and funding multi-centre, multi-disciplinary research Canada wide, C¹⁷ is reducing barriers to access to research studies and thereby increasing treatment and research opportunities for all children to participate in the improving of health outcomes and the quality of life. Funding for the competition is partnered with Childhood Cancer Canada and The Kids With Cancer Society (Edmonton).

The 100% Fund 

Nearly one in five children diagnosed with cancer will not survive. For children with rare and hard to treat cancers, the odds can be far worse. The 100% Fund has been created to challenge these odds.  Fight Like Mason, Team Finn, #JaidasJourney - The Jaida Chartier Foundation, Phoebe Rose Rocks, Sarcoma Research Canada, Kindred Foundation and Childhood Cancer Canada have partnered to fund  research for children and teens who do not, yet, have their cure.

The 100% Fund focuses on hard‑to‑treat pediatric and adolescent cancers that have not responded to available therapies, channeling partner support into projects with potential to improve treatment and survival for these populations.

See the Research Grants page for previously funded grants.

The 100% Fund Grant Competition (Round 6, 2025) - 
Diffuse Midline Glioma (DMG) / Diffuse Intrinsic Pontine Glioma (DIPG) and Rhabdomyosarcoma

The 100% Fund targets pediatric and adolescent cancers that are hard to treat — cancers that have not responded to available therapies. The goal is to fund research with the potential to deliver improved treatment and increased survival rates.

We will accept one application addressing each of the following research areas in consideration of the Round 6 2025 grant competition:

• DMG / DIPG
• Rhabdomyosarcoma

Guidance Documents and Application Forms for the 100% Fund Grant Competition (Round 6)

• 100% Fund Grant Call for Applications and Instructions
• 100% Fund Grant Application Form 
• C17 Grant Application Instructions and Award Guide (ver 01May2023)

Deadlines:

• Registration by email: Friday OCTOBER 24, 2025
• Grant Submission: Friday NOVEMBER 21, 2025

Questions & Registration: evani.goll@c17.ca

For further information on the C¹⁷ Research Network contact: